108 related articles for article (PubMed ID: 33469839)
21. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
22. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma.
Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Zhu X; Zhao P; Zhao J; Liu J; Chen N; Wang J; Shen P; Zeng H
BMC Cancer; 2019 Apr; 19(1):360. PubMed ID: 30992011
[TBL] [Abstract][Full Text] [Related]
23. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of PD-L1 and PD-L2 in breast cancer.
Baptista MZ; Sarian LO; Derchain SF; Pinto GA; Vassallo J
Hum Pathol; 2016 Jan; 47(1):78-84. PubMed ID: 26541326
[TBL] [Abstract][Full Text] [Related]
25. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
26. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
Stanisavljević L; Myklebust MP; Leh S; Dahl O
Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
[TBL] [Abstract][Full Text] [Related]
27. Quantitative proteomics reveals that distant recurrence-associated protein R-Ras and Transgelin predict post-surgical survival in patients with Stage III colorectal cancer.
Xu L; Gao Y; Chen Y; Xiao Y; He Q; Qiu H; Ge W
Oncotarget; 2016 Jul; 7(28):43868-43893. PubMed ID: 27270312
[TBL] [Abstract][Full Text] [Related]
28. PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
Takamori S; Takada K; Toyokawa G; Azuma K; Shimokawa M; Jogo T; Yamada Y; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Anticancer Res; 2018 Oct; 38(10):5897-5901. PubMed ID: 30275216
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers.
Kim MY; Koh J; Kim S; Go H; Jeon YK; Chung DH
Lung Cancer; 2015 Apr; 88(1):24-33. PubMed ID: 25662388
[TBL] [Abstract][Full Text] [Related]
32. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer.
Wu Y; Zhao T; Jia Z; Cao D; Cao X; Pan Y; Zhao D; Zhang B; Jiang J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1201-1207. PubMed ID: 30353572
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
34. Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.
Okuda Y; Shimura T; Yamada T; Hirata Y; Yamaguchi R; Sakamoto E; Kataoka H
Int J Clin Oncol; 2018 Dec; 23(6):1101-1111. PubMed ID: 29948240
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
[TBL] [Abstract][Full Text] [Related]
36. Programmed death-ligand 2 (PD-L2) expression in bladder cancer.
Yang Y; Wang X; Bai Y; Feng D; Li A; Tang Y; Wei X; Han P
Urol Oncol; 2020 Jun; 38(6):603.e9-603.e15. PubMed ID: 32151519
[TBL] [Abstract][Full Text] [Related]
37. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
[TBL] [Abstract][Full Text] [Related]
38. Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
Shinchi Y; Komohara Y; Yonemitsu K; Sato K; Ohnishi K; Saito Y; Fujiwara Y; Mori T; Shiraishi K; Ikeda K; Suzuki M
Cancer Sci; 2019 Sep; 110(9):2711-2721. PubMed ID: 31294893
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer.
Wang L; Liu Z; Fisher KW; Ren F; Lv J; Davidson DD; Baldridge LA; Du X; Cheng L
Hum Pathol; 2018 Jan; 71():20-29. PubMed ID: 28782638
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death-Ligand 1 and Programmed Death-Ligand 2 Expression Can Affect Prognosis in Extramammary Paget's Disease.
Kawaguchi A; Akiba J; Kondo R; Sadashima E; Ogasawara S; Naito Y; Kusano H; Sanada S; Muto I; Nakama T; Yano H
Anticancer Res; 2021 Jan; 41(1):219-226. PubMed ID: 33419816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
